Novo Nordisk and NanoVation to develop genetic medicines in partnership worth $600m
Novo Nordisk and NanoVation Therapeutics have entered into a multi-year partnership worth $600m to advance genetic medicines for cardiometabolic and rare diseases. The deal combines Novo’s capabilities in the two areas with NanoVation’s proprietary long- …